npj Parkinson's Disease (Mar 2024)
Genotype–phenotype correlation in PRKN-associated Parkinson’s disease
- Poornima Jayadev Menon,
- Sara Sambin,
- Baptiste Criniere-Boizet,
- Thomas Courtin,
- Christelle Tesson,
- Fanny Casse,
- Melanie Ferrien,
- Louise-Laure Mariani,
- Stephanie Carvalho,
- Francois-Xavier Lejeune,
- Sana Rebbah,
- Gaspard Martet,
- Marion Houot,
- Aymeric Lanore,
- Graziella Mangone,
- Emmanuel Roze,
- Marie Vidailhet,
- Jan Aasly,
- Ziv Gan Or,
- Eric Yu,
- Yves Dauvilliers,
- Alexander Zimprich,
- Volker Tomantschger,
- Walter Pirker,
- Ignacio Álvarez,
- Pau Pastor,
- Alessio Di Fonzo,
- Kailash P. Bhatia,
- Francesca Magrinelli,
- Henry Houlden,
- Raquel Real,
- Andrea Quattrone,
- Patricia Limousin,
- Prasad Korlipara,
- Thomas Foltynie,
- Donald Grosset,
- Nigel Williams,
- Derek Narendra,
- Hsin-Pin Lin,
- Carna Jovanovic,
- Marina Svetel,
- Timothy Lynch,
- Amy Gallagher,
- Wim Vandenberghe,
- Thomas Gasser,
- Kathrin Brockmann,
- Huw R. Morris,
- Max Borsche,
- Christine Klein,
- Olga Corti,
- Alexis Brice,
- Suzanne Lesage,
- Jean Christophe Corvol,
- French Parkinson disease Genetics Study Group (PDG)
Affiliations
- Poornima Jayadev Menon
- Sorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS
- Sara Sambin
- Sorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS
- Baptiste Criniere-Boizet
- Sorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS
- Thomas Courtin
- Sorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS
- Christelle Tesson
- Sorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS
- Fanny Casse
- Sorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS
- Melanie Ferrien
- Sorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS
- Louise-Laure Mariani
- Sorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS
- Stephanie Carvalho
- Sorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS
- Francois-Xavier Lejeune
- Sorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS
- Sana Rebbah
- Sorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS
- Gaspard Martet
- Sorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS
- Marion Houot
- Sorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS
- Aymeric Lanore
- Sorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS
- Graziella Mangone
- Sorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS
- Emmanuel Roze
- Sorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS
- Marie Vidailhet
- Sorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS
- Jan Aasly
- Department of Neurology, Norwegian University of Science and Technology
- Ziv Gan Or
- The Neuro (Montreal Neurological Institute-Hospital), McGill University
- Eric Yu
- The Neuro (Montreal Neurological Institute-Hospital), McGill University
- Yves Dauvilliers
- Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier, University of Montpellier, Institute for Neurosciences of Montpellier (INM), INSERM
- Alexander Zimprich
- Department of Neurology, University Hospital Vienna
- Volker Tomantschger
- Gailtal-Klinik Hermagor
- Walter Pirker
- Department of Neurology, Ottakring Clinic
- Ignacio Álvarez
- Department of Neurology, Hospital Universitari Mutua de Terrassa, and Fundació per a la Recerca Biomèdica i Social Mútua de Terrassa
- Pau Pastor
- Unit of Neurodegenerative diseases, Department of Neurology, University Hospital Germans Trias i Pujol and The Germans Trias i Pujol Research Institute (IGTP) Badalona
- Alessio Di Fonzo
- Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico
- Kailash P. Bhatia
- Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London
- Francesca Magrinelli
- Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London
- Henry Houlden
- Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology
- Raquel Real
- Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London
- Andrea Quattrone
- Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London
- Patricia Limousin
- Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London
- Prasad Korlipara
- Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London
- Thomas Foltynie
- Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London
- Donald Grosset
- Institute of Neurological Sciences, University of Glasgow
- Nigel Williams
- Department of Psychological Medicine and Neurology, Cardiff University
- Derek Narendra
- Inherited Disorders Unit, Neurogenetics Branch, Division of Intramural Research, National Institute of Neurological Disorders and Stroke, National Institutes of Health
- Hsin-Pin Lin
- Inherited Disorders Unit, Neurogenetics Branch, Division of Intramural Research, National Institute of Neurological Disorders and Stroke, National Institutes of Health
- Carna Jovanovic
- University Clinical Center of Serbia, Neurology Clinic
- Marina Svetel
- University Clinical Center of Serbia, Neurology Clinic
- Timothy Lynch
- The Dublin Neurological Institute at the Mater Misericordiae University Hospital, Dublin Ireland and University College Dublin
- Amy Gallagher
- The Dublin Neurological Institute at the Mater Misericordiae University Hospital, Dublin Ireland and University College Dublin
- Wim Vandenberghe
- Department of Neurology, University Hospitals Leuven; Department of Neurosciences, KU Leuven; Leuven Brain Institute
- Thomas Gasser
- Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen
- Kathrin Brockmann
- Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen
- Huw R. Morris
- Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London
- Max Borsche
- Institute of Neurogenetics, University of Lübeck
- Christine Klein
- Institute of Neurogenetics, University of Lübeck
- Olga Corti
- Sorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS
- Alexis Brice
- Sorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS
- Suzanne Lesage
- Sorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS
- Jean Christophe Corvol
- Sorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS
- French Parkinson disease Genetics Study Group (PDG)
- DOI
- https://doi.org/10.1038/s41531-024-00677-3
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 12
Abstract
Abstract Bi-allelic pathogenic variants in PRKN are the most common cause of autosomal recessive Parkinson’s disease (PD). 647 patients with PRKN-PD were included in this international study. The pathogenic variants present were characterised and investigated for their effect on phenotype. Clinical features and progression of PRKN-PD was also assessed. Among 133 variants in index cases (n = 582), there were 58 (43.6%) structural variants, 34 (25.6%) missense, 20 (15%) frameshift, 10 splice site (7.5%%), 9 (6.8%) nonsense and 2 (1.5%) indels. The most frequent variant overall was an exon 3 deletion (n = 145, 12.3%), followed by the p.R275W substitution (n = 117, 10%). Exon3, RING0 protein domain and the ubiquitin-like protein domain were mutational hotspots with 31%, 35.4% and 31.7% of index cases presenting mutations in these regions respectively. The presence of a frameshift or structural variant was associated with a 3.4 ± 1.6 years or a 4.7 ± 1.6 years earlier age at onset of PRKN-PD respectively (p < 0.05). Furthermore, variants located in the N-terminus of the protein, a region enriched with frameshift variants, were associated with an earlier age at onset. The phenotype of PRKN-PD was characterised by slow motor progression, preserved cognition, an excellent motor response to levodopa therapy and later development of motor complications compared to early-onset PD. Non-motor symptoms were however common in PRKN-PD. Our findings on the relationship between the type of variant in PRKN and the phenotype of the disease may have implications for both genetic counselling and the design of precision clinical trials.